healthfirst
Health Insurance for New Yorkers

Provider Alert

Update: Medicare Monoclonal Antibody COVID-19 Infusion Program

COVID-19: EUA for Sotrovimab Monoclonal Antibody Product

On May 26, 2021, the U.S. Food and Drug Administration (FDA) released an Emergency Use Authorization (EUA) for sotrovimab, a COVID-19 monoclonal antibody product. CMS created new HCPCS codes, effective May 26, 2021, for sotrovimab and to administer sotrovimab in healthcare settings and the home (see below).

COVID-19: EUA for Regeneron Monoclonal Antibody Product Casirivimab & Imdevimab

On June 3, 2021, the FDA released a revised Emergency Use Authorization (EUA) for Regeneron's COVID-19 monoclonal antibody combination product casirivimab and imdevimab. The updated EUA includes a new dosing regimen (1200 mg vs. 2400 mg) and allows a new route of administration.

In response to this change, CMS created a new HCPCS code, effective June 3, 2021, and updated the short and long code descriptors for 2 codes.

Coding for Monoclonal Antibody Products to Treat COVID-19

CMS identified specific code(s) for each monoclonal antibody product to treat COVID-19 and specific administration code(s) for Medicare payment:

Product	EUA Effective & Revocation Date(s)	Specific Code	Administration Code
Eli Lilly and Company's Antibody Bamlanivimab (LY-CoV555)	November 10, 2020 to April 16, 2021 **Note:** On April 16, 2021, the FDA revoked the EUA for bamlanivimab when administered alone.	Q0239 **Long descriptor:** Injection, bamlanivimab-xxxx, 700 mg **Short descriptor:** bamlanivimab-xxxx	M0239 **Long descriptor:** intravenous infusion, bamlanivimab-xxxx, includes infusion and post-administration monitoring **Short descriptor:** bamlanivimab-xxxx infusion

Product	EUA Effective & Revocation Date(s)	Specific Code	Administration Code
Regeneron's Antibody casirivimab and imdevimab (REGN-COV2) (ZIP)	November 21, 2020 to TBD	Q0243 **Long descriptor:** Injection, casirivimab and imdevimab, 2,400 mg **Short descriptor:** casirivimab and imdevimab Q0244 (Code effective 06/03/2021 and reflects updated dosing regimen) **Long descriptor:** Injection, casirivimab and imdevimab, 1200 mg **Short descriptor:** Casirivi and imdevi 1200 mg	M0243 **Long descriptor:** intravenous infusion, casirivimab and imdevimab includes infusion and post-administration monitoring **Short descriptor:** casirivi and imdevi infusion
Regeneron's Antibody casirivimab and imdevimab (REGN-COV2) (ZIP)	November 21, 2020 – TBD Note: While the product EUA was issued on November 21, 2020, this administration code is effective May 6, 2021	Q0243 **Long descriptor:** Injection, casirivimab and imdevimab, 2400 mg **Short descriptor:** Casirivimab and imdevimab Q0244 (Code effective 06/03/2021 and reflects updated dosing regimen) **Long descriptor:** Injection, casirivimab and imdevimab, 1200 mg **Short descriptor:** Casirivi and imdevi 1200 mg	M0244 **Long Descriptor:** Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post-administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the COVID-19 public health emergency[1] **Short Descriptor:** Casirivi and imdevi inj hm

Product	EUA Effective & Revocation Date(s)	Specific Code	Administration Code
Eli Lilly and Company's Antibody Bamlanivimab and Etesevimab, (ZIP)	February 9, 2021 to TBD	Q0245 **Long descriptor:** Injection, bamlanivimab and etesevimab, 2,100 mg **Short descriptor:** bamlanivimab and etesevimab	M0245 **Long descriptor:** intravenous infusion, bamlanivimab and etesevimab, includes infusion and post-administration monitoring **Short descriptor:** bamlan and etesev infusion
Eli Lilly and Company's Antibody Bamlanivimab and Etesevimab, (ZIP)	February 9, 2021 (reissued on February 25, 2021) to TBD Note: While the product EUA was issued on February 9, 2021, this administration code is effective May 6, 2021	Q0245 **Long Descriptor:** Injection, bamlanivimab and etesevimab, 2100 mg **Short Descriptor:** Bamlanivimab and etesevima	M0246 **Long Descriptor:** Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post-administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the COVID-19 public health emergency[1] **Short Descriptor:** Bamlan and etesev infus home
GlaxoSmith Kline's Antibody Sotrovimab	May 26, 2021 to TBD	Q0247 **Long descriptor:** Injection, sotrovimab, 500 mg **Short descriptor:** Sotrovimab	M0247 **Long Descripor:** Intravenous infusion, sotrovimab, includes infusion and post-administration monitoring **Short Descriptor:** Sotrovimab infusion

Product	EUA Effective & Revocation Date(s)	Specific Code	Administration Code
GlaxoSmith Kline's Antibody Sotrovimab	May 26, 2021 to TBD	Q0247 **Long descriptor:** Injection, sotrovimab, 500 mg **Short descriptor:** Sotrovimab	M0248 **Long Descriptor:** Intravenous infusion, sotrovimab, includes infusion and post-administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the COVID-19 public health emergency[1] **Short Descriptor:** Sotrovimab inf, home admin
Genentech's Antibody Tocilizumab	June 24, 2021 to TBD	Q02492 **Long descriptor:** Injection, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with COVID-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) only, 1 mg **Short descriptor:** Tocilizumab for COVID-19	M0249 **Long Descriptor:** Intravenous infusion, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with COVID-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) only, includes infusion and post-administration monitoring, first dose **Short Descriptor:** Adm Tocilizu COVID-19 1st

Product	EUA Effective & Revocation Date(s)	Specific Code	Administration Code
Genentech's Antibody Tocilizumab	June 24, 2021 to TBD	Q02492 **Long descriptor:** Injection, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with COVID-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) only, 1 mg **Short descriptor:** Tocilizumab for COVID-19	M0250 **Long descriptor:** Intravenous infusion, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with COVID-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) only, includes infusion and post-administration monitoring, second dose **Short descriptor:** Adm Tocilizu COVID-19 2nd

If you have any questions, contact your Network Account Manager, or call Provider Services at **1-888-801-1660**, Monday to Friday, 8:30am–5:30pm.

*Source: **FDA NEWS RELEASE**, Coronavirus (COVID-19) Update: FDA Revokes Emergency Use Authorization for Monoclonal Antibody Bamlanivimab, April 16, 2021.

[2]Given the limited clinical situations allowed under the EUA, you should only bill for tocilizumab on a 12x type of bill (TOB).

Updated as of 08/2021